Abstract
Imatinib mesylate is the first and only effective drug for the treatment of gastrointestinal stromal tumor at present. Mutated exon 11 of the KIT receptor is essential for the pathogenesis and response to imatinib mesylate of gastrointestinal stromal tumor; the efficacy rate (complete response + partial response) of imatinib mesylate is 53.8%, and the disease-control rate (complete response + partial response + stable disease) is 84%. Almost 90% of patients experienced non-hematological and hematological adverse effects, which were tolerable, in particular at a daily dose of 400 mg imatinib mesylate, which warranted response induction for half of the patients, and is the dose approved by Japanese medical insurance. Clinical trials suggest that an increased dose of imatinib mesylate would be beneficial, and that the interruption of imatinib treatment might result in disease progression even after a partial response. Tentative Japanese guidelines for the diagnosis and therapy of gastrointestinal stromal tumors are being prepared by the Gastrointestinal Stromal Tumor Committee of the Japan Society of Clinical Oncology, and are presented here for critical comments by colleagues.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S Hirota K Isozaki Y Moriyama et al. (1998) ArticleTitleGain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577–580 Occurrence Handle9438854 Occurrence Handle1:CAS:528:DyaK1cXotVyhsw%3D%3D Occurrence Handle10.1126/science.279.5350.577
GD Demetri M von Mehren CD Blanke et al. (2002) ArticleTitleEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472–480 Occurrence Handle12181401 Occurrence Handle1:CAS:528:DC%2BD38XmtV2nt7s%3D Occurrence Handle10.1056/NEJMoa020461
MC Heinrich CL Corless GD Demetri et al. (2003) ArticleTitleKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 4342–4349 Occurrence Handle14645423 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWqu7Y%3D Occurrence Handle10.1200/JCO.2003.04.190
H Sihto M Sarlomo-Rikala O Tynninen et al. (2005) ArticleTitleKIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors J Clin Oncol 23 49–57 Occurrence Handle15545668 Occurrence Handle1:CAS:528:DC%2BD2MXpslaksg%3D%3D Occurrence Handle10.1200/JCO.2005.02.093
C Tarn E Merkel AA Canutescu et al. (2005) ArticleTitleAnalysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling Clin Cancer Res 11 3668–3677 Occurrence Handle15897563 Occurrence Handle1:CAS:528:DC%2BD2MXktFyrtrs%3D Occurrence Handle10.1158/1078-0432.CCR-04-2515
AT van Oosterom IR Judson J Verweij et al. (2002) ArticleTitleUpdate of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 38 IssueIDSuppl 5 S83–S87 Occurrence Handle12528778 Occurrence Handle10.1016/S0959-8049(02)80608-6
J Verweij A van Oosterom JY Blay et al. (2003) ArticleTitleImatinib mesylate (STI-571 Glivec1, GleevecTM) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur J Cancer 39 2006–2011 Occurrence Handle12957454 Occurrence Handle1:CAS:528:DC%2BD3sXmvVKgtrc%3D Occurrence Handle10.1016/S0959-8049(02)00836-5
J Verweij PG Casali J Zalcberg et al. (2004) ArticleTitleProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127–1134 Occurrence Handle15451219 Occurrence Handle1:CAS:528:DC%2BD2cXnvVOiu7o%3D Occurrence Handle10.1016/S0140-6736(04)17098-0
JR Zalcberg J Verweij PG Casali et al. (2004) ArticleTitleOutcome of patients with advanced gastro-intestinal stromal tumor (GIST) crossing over to daily imatinib does of 800 mg (HD) after progression on 400 mg (LD) – an international, intergroup study of the EORTC, ISG and AGITG. 9 (abstract #9004) Proc ASCO 23 815
JY Blay P Berthaud D Perol et al. (2004) ArticleTitleContinuous vs intermittent imatinib treatment in advanced GIST after 1 year: a prospective randomized phase III trial of the French Sarcoma Group (abstract #9006) Proc ASCO 23 815
LL Chen M Sabripour RHI Andtbacka et al. (2005) ArticleTitleImatinib resistance in gastrointestinal stromal tumors Curr Oncol Rep 7 293–299 Occurrence Handle15946589 Occurrence Handle1:CAS:528:DC%2BD28XktVarsw%3D%3D
GD Demetri J Desai JA Fletcher et al. (2004) ArticleTitleSU11248, a multitargeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) (abstract #3001) Proc ASCO 23 195
RG Maki JA Fletcher MC Heinrich et al. (2005) ArticleTitleResults from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) (abstract #9011) Proc ASCO 24 818s
GD Demetri RB Benjamin CD Blanke et al. (2004) ArticleTitleNCCN task force report: optimal management of patients with gastrointestinal stromal tumor (GIST) – Expansion and update of NCCN clinical practice guidelines J Natl Compr Canc Netw 2 IssueIDSuppl 1 S-1–S-26
JY Blay S Bonvalot P Casali et al. (2005) ArticleTitleConsensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO Ann Oncol 6 566–578 Occurrence Handle10.1093/annonc/mdi127
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kubota, T. Gastrointestinal stromal tumor (GIST) and imatinib. Int J Clin Oncol 11, 184–189 (2006). https://doi.org/10.1007/s10147-006-0579-0
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10147-006-0579-0